Mankind Pharma Limited

Mankind Pharma Limited, established in 1991, is a prominent Indian pharmaceutical and healthcare company headquartered in New Delhi. The company was founded by brothers Ramesh C. Juneja and Rajeev Juneja, who began operations with a seed capital of ₹20,000 and a team of 20 employees. Over the years, Mankind Pharma has expanded its product portfolio to include pharmaceuticals, generic drugs, over-the-counter (OTC) products, fast-moving consumer goods (FMCG), and diagnostics.

As of 2023, Mankind Pharma operates 25 manufacturing facilities and 6 research and development centers across India. The company employs over 22,000 individuals, reflecting its significant presence in the pharmaceutical industry. In the fiscal year ending March 31, 2025, Mankind Pharma reported a revenue of ₹10,335 crore, with domestic revenue accounting for ₹9,522 crore. The company's registered office is located at 208, Okhla Industrial Estate, Phase-III, New Delhi, Delhi - 110020.

Mankind Pharma's manufacturing operations are extensive, with 25 factories strategically located across India. These facilities are equipped to produce a wide range of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's manufacturing plants adhere to stringent quality standards, ensuring the production of safe and effective medications. Specific details regarding the capacities and specializations of each plant are proprietary and not publicly disclosed.

The leadership team at Mankind Pharma is headed by Chairman and Managing Director Ramesh C. Juneja, who co-founded the company and has been instrumental in its growth and success. Rajeev Juneja serves as the Vice Chairman and Managing Director, contributing significantly to the company's strategic direction and operations. Sheetal Arora holds the position of Chief Executive Officer, overseeing the company's day-to-day operations and ensuring alignment with its long-term objectives. Other key executives include Arjun Juneja, the Chief Operating Officer, and Pradeep Chugh, the Company Secretary and Compliance Officer.

Mankind Pharma has made significant strides in regulated markets, particularly in the United States. In June 2021, the company launched Justoza, a Dapagliflozin brand approved by the US FDA, marking its entry into the US market. The Active Pharmaceutical Ingredient (API) for Justoza is sourced from a US FDA-approved Drug Master File (DMF) facility, ensuring adherence to global efficacy and safety standards. While specific details regarding regulatory filings and approvals in the European Union, United Kingdom, Australia, and Japan are not publicly available, Mankind Pharma's commitment to quality and compliance suggests a proactive approach to meeting international regulatory requirements.

Mankind Pharma has expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's diverse product portfolio, encompassing pharmaceuticals, OTC products, and FMCG items, positions it well to cater to the healthcare needs of these regions. In November 2025, Mankind Pharma entered into a licensing agreement with Actimed Therapeutics Ltd, granting exclusive rights to develop and commercialize Actimed's products for the treatment and prevention of cachexia in India and South Asian territories. This strategic move underscores Mankind Pharma's commitment to addressing critical health issues in emerging markets.

Mankind Pharma's geographic strategy reflects a balanced approach, with a strong domestic presence complemented by strategic expansions into international markets. The company's focus on affordability, quality, and accessibility has facilitated its growth in both domestic and international arenas. While the company has a significant footprint in India, its ventures into regulated and emerging markets indicate a strategic diversification aimed at mitigating concentration risks and tapping into new growth opportunities.

Mankind Pharma has demonstrated its commitment to meeting international standards by obtaining FDA approval for its product Justoza, a Dapagliflozin brand launched in June 2021. The API for Justoza is sourced from a US FDA-approved DMF facility, ensuring compliance with global efficacy and safety standards. Specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. However, the approval of Justoza indicates a proactive approach by Mankind Pharma in adhering to FDA regulations.

Mankind Pharma's commitment to quality is evident in its adherence to Good Manufacturing Practices (GMP) standards. The company sources its APIs from facilities that are approved by the World Health Organization (WHO) and the European Union (EU) GMP, ensuring compliance with international quality standards. While specific details regarding WHO prequalification and EU GMP certificates are not publicly available, the company's sourcing practices reflect a dedication to maintaining high-quality manufacturing processes.

Mankind Pharma operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses issued by CDSCO, authorizing it to produce a wide range of pharmaceutical formulations. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed. However, Mankind Pharma's extensive domestic operations and export activities suggest compliance with Indian regulatory requirements.

As of March 28, 2026, there are no publicly available records indicating that Mankind Pharma has received any Form 483 observations, warning letters, or import alerts from regulatory authorities. The company's proactive approach to quality and compliance, as evidenced by its adherence to international standards and regulatory approvals, suggests a strong track record in maintaining regulatory compliance.

Mankind Pharma operates in a competitive landscape, with several key players in the Indian pharmaceutical industry. While specific market share data is not publicly available, Mankind Pharma's diverse product portfolio and strategic initiatives position it as a significant competitor in both domestic and international markets. The company's focus on affordability, quality, and accessibility has contributed to its growth and competitive standing.

Mankind Pharma's key differentiators include its extensive product portfolio, encompassing pharmaceuticals, OTC products, and FMCG items, catering to a wide range of consumer needs. The company's commitment to affordability, quality, and accessibility has facilitated its growth and market penetration. Strategic initiatives, such as the licensing agreement with Actimed Therapeutics Ltd in November 2025, demonstrate Mankind Pharma's proactive approach to addressing critical health issues and expanding its product offerings.

Mankind Pharma's current strategic direction focuses on expanding its presence in both domestic and international markets. The company's diverse product portfolio, including generics, specialty products, and OTC items, reflects a balanced approach to addressing various market segments. Future outlooks suggest continued growth through strategic partnerships, such as the licensing agreement with Actimed Therapeutics Ltd, and potential expansions into new therapeutic areas and markets.

Mankind Pharma's supplier assessment indicates a strong track record in sourcing high-quality APIs from facilities approved by international regulatory bodies, including the US FDA, EU GMP, and WHO GMP. The company's proactive approach to quality assurance and regulatory compliance suggests reliability and consistency in its supply chain operations. While specific export volumes and consistency metrics are not publicly disclosed, Mankind Pharma's extensive domestic and international operations reflect a robust and dependable supply chain.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Approval: Confirm that the product is approved by the US Food and Drug Administration (FDA). This can be verified through the FDA's official website or by contacting the manufacturer directly.

• WHO-GMP Certification: Ensure that the manufacturing facility adheres to World Health Organization's Good Manufacturing Practices (GMP). This information is typically available on the manufacturer's website or can be obtained by contacting them directly.

• EU GMP Certification: Verify that the facility complies with European Union's Good Manufacturing Practices. This certification can be confirmed through the manufacturer's official communications or by reaching out to them directly.

• ISO Certification: Check for International Organization for Standardization (ISO) certifications, which indicate adherence to international quality standards. These certifications are usually listed on the manufacturer's website or can be obtained by contacting them.

Importers should undertake the following steps to ensure